Helena Linardou1, Vassiliki Kotoula2,3, George Kouvatseas4, Giannis Mountzios5, Vasilios Karavasilis6, Epaminondas Samantas7, Anna Kalogera-Fountzila8, Despina Televantou3, Kyriaki Papadopoulou3, Xanthipi Mavropoulou8, Emily Daskalaki2, Thomas Zaramboukas2, Ioannis Efstratiou9, Sofia Lampaki6, Grigorios Rallis6, Eleni Res7, Konstantinos N Syrigos10, Paris A Kosmidis11, Dimitrios Pectasides12, George Fountzilas3,13. 1. Oncology Unit, Metropolitan Hospital, Athens, Greece elinardou@otenet.gr. 2. Department of Pathology, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki, Greece. 3. Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece. 4. Health Data Specialists Ltd, Athens, Greece. 5. Second Oncology Department, Henry Dunant Hospital Center, Athens, Greece. 6. Department of Medical Oncology, Papageorgiou Hospital, Faculty of Medicine, Aristotle University of Thessaloniki, School of Health Sciences, Thessaloniki, Greece. 7. Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece. 8. Department of Radiology, AHEPA Hospital, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. 9. Department of Pathology, Papageorgiou Hospital, Thessaloniki, Greece. 10. Oncology Unit GPP, Sotiria General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece. 11. Second Department of Medical Oncology, Hygeia Hospital, Athens, Greece. 12. Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece. 13. Aristotle University of Thessaloniki, Thessaloniki, Greece.
Abstract
BACKGROUND/AIM: KRAS mutations are reported in 20-25% of non-small cell lung cancer (NSCLC) and their prognostic role is unclear. We studied KRAS and EGFR genotyping in Greek NSCLC patients. PATIENTS AND METHODS: KRAS and EGFR genotypes were centrally evaluated in 421 NSCLC patients (diagnosed September 1998 -June 2013) and associated with clinicopathological parameters. Outcome comparisons were performed in 288 patients receiving first line treatment. RESULTS: Most patients were male (78.6%), >60 years old (63.9%), current smokers (51.1%), with adenocarcinoma histology (63.9%). EGFR and KRAS mutations were found in 10.7% and 16.6% of all histologies, respectively, and in 14.9% and 21.9% of adenocarcinomas. At 4.5 years median follow-up, KRAS status was an independent negative prognostic factor for overall survival (OS, p=0.016). KRAS mutations conferred 80% increased risk of death in patients receiving first-line treatment (p=0.002). CONCLUSION: The presence of KRAS mutations is an independent negative prognosticator among Greek NSCLC patients and an independent response predictor to first line treatment. Copyright
BACKGROUND/AIM: KRAS mutations are reported in 20-25% of non-small cell lung cancer (NSCLC) and their prognostic role is unclear. We studied KRAS and EGFR genotyping in Greek NSCLCpatients. PATIENTS AND METHODS: KRAS and EGFR genotypes were centrally evaluated in 421 NSCLCpatients (diagnosed September 1998 -June 2013) and associated with clinicopathological parameters. Outcome comparisons were performed in 288 patients receiving first line treatment. RESULTS: Most patients were male (78.6%), >60 years old (63.9%), current smokers (51.1%), with adenocarcinoma histology (63.9%). EGFR and KRAS mutations were found in 10.7% and 16.6% of all histologies, respectively, and in 14.9% and 21.9% of adenocarcinomas. At 4.5 years median follow-up, KRAS status was an independent negative prognostic factor for overall survival (OS, p=0.016). KRAS mutations conferred 80% increased risk of death in patients receiving first-line treatment (p=0.002). CONCLUSION: The presence of KRAS mutations is an independent negative prognosticator among Greek NSCLCpatients and an independent response predictor to first line treatment. Copyright
Authors: Anna Szumera-Ciećkiewicz; Włodzimierz T Olszewski; Andrzej Tysarowski; Dariusz M Kowalski; Maciej Głogowski; Maciej Krzakowski; Janusz A Siedlecki; Michał Wągrodzki; Monika Prochorec-Sobieszek Journal: Int J Clin Exp Pathol Date: 2013-11-15
Authors: Martin Svaton; Ondrej Fiala; Milos Pesek; Zbynek Bortlicek; Marek Minarik; Lucie Benesova; Ondrej Topolcan Journal: Anticancer Res Date: 2016-03 Impact factor: 2.480
Authors: Gregory J Riely; Mark G Kris; Daniel Rosenbaum; Jenifer Marks; Allan Li; Dhananjay A Chitale; Khedoudja Nafa; Elyn R Riedel; Meier Hsu; William Pao; Vincent A Miller; Marc Ladanyi Journal: Clin Cancer Res Date: 2008-09-15 Impact factor: 12.531
Authors: Rodrigo Cavagna; Flávia Escremim de Paula; Débora Sant'Anna; Iara Santana; Vinicius D da Silva; Eduardo C A da Silva; Carlos E Bacchi; José E Miziara; Josiane M Dias; Pedro De Marchi; Leticia F Leal; Rui M Reis Journal: JCO Glob Oncol Date: 2021-04
Authors: Tina Lamy; Bastien Cabarrou; David Planchard; Xavier Quantin; Sophie Schneider; Michael Bringuier; Benjamin Besse; Nicolas Girard; Christos Chouaid; Thomas Filleron; Gaëtane Simon; Capucine Baldini Journal: Cancers (Basel) Date: 2021-12-24 Impact factor: 6.639